Related Experiment Video
Updated: Nov 14, 2025
Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment
Published on: June 28, 2018
Recent advances in preclinical models for lung squamous cell carcinoma
Yuanwang Pan1, Han Han1, Kristen E Labbe1
1Division of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
Abstract:
Lung squamous cell carcinoma (LUSC) represents a major subtype of non-small cell lung cancer with limited treatment options. Previous studies have elucidated the complex genetic landscape of LUSC and revealed multiple altered genes and pathways. However, in stark contrast to lung adenocarcinoma, few targetable driver mutations have been established so far and targeted therapies for LUSC remain unsuccessful. Immunotherapy has revolutionized LUSC treatment and is currently approved as the new standard of care. To gain a better understanding of the LUSC biology, improved modeling systems are urgently needed. Preclinical models, particularly those mimicking human disease with an intact tumor immune microenvironment, are an invaluable tool to study cancer development and evaluate new therapeutic targets. Here, we discuss recent advances in LUSC preclinical models, with a focus on genetically engineered mouse models (GEMMs) and organoids, in the context of evolving precision medicine and immunotherapy.
Insights
Developing better preclinical models for lung squamous cell carcinoma (LUSC) is crucial. Genetically engineered mouse models and organoids offer promising avenues for understanding LUSC and advancing precision medicine and immunotherapy.
Area of Science:
- Oncology
- Cancer Biology
- Translational Medicine
Background:
- Lung squamous cell carcinoma (LUSC) is a significant non-small cell lung cancer subtype with limited targeted therapy options.
- While immunotherapy has advanced LUSC treatment, a deeper understanding of LUSC biology is needed.
- Effective preclinical models are essential for studying cancer development and evaluating novel therapeutic strategies.
Purpose of the Study:
- To review recent advancements in LUSC preclinical models.
- To highlight the importance of models that preserve the tumor immune microenvironment.
- To discuss the role of these models in precision medicine and immunotherapy for LUSC.
Main Methods:
- Focus on genetically engineered mouse models (GEMMs) for LUSC.
- Discussion of organoid models for LUSC research.
- Integration of preclinical models within the context of precision medicine and immunotherapy.
Main Results:
- GEMMs and organoids are increasingly sophisticated tools for LUSC research.
- These models facilitate the study of LUSC under conditions that mimic the human tumor immune microenvironment.
- Advances in modeling are critical for identifying new therapeutic targets and strategies.
Conclusions:
- Improved preclinical models are vital for advancing LUSC research and treatment.
- Genetically engineered mouse models and organoids are key to understanding LUSC biology and response to therapy.
- These models are instrumental in the development of precision medicine and immunotherapy for LUSC.
